FAQs and Guidances

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Federal government:

Professional societies:

  • American Society of Clinical Oncology FAQ: Emerging issues and challenges in caring for patients with cancer during the coronavirus pandemic

  • American Cancer Society FAQ: Common questions about the new coronavirus outbreak

  • Society for Immunotherapy of Cancer Resources: Patient management and basic and translational research

  • Community Oncology Alliance resources: Coronavirus (COVID-19) practice resources and protocols

  • Leukemia & Lymphoma Society FAQ: Resources and what you should know about the coronavirus

  • American Society for Radiation Oncology FAQ: COVID-19 recommendations and information

  • American College of Surgeons resources: For the surgical community

  • Society for Immunotherapy of Cancer resources: Implications for patients, translational research

  • American Society for Transplantation and Cellular Therapy resources

  • European Blood and Marrow Transplantation Society recommendations

  • World Marrow Donor Association resources

Research centers:

  • St. Jude Children’s Research Hospital FAQ: COVID-19 and children with cancer

  • Journal of the National Comprehensive Cancer Network: How to manage cancer care during COVID-19 pandemic

Table of Contents

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login